in the 298 allocated to CEB (log-rank x 2 = 2 6 .9 ; P < .001), which led to failure-free rates at 1 y e a r of 91% (95% confidence interval [Cl], 88% to 94%) and 77% (95% Cl, 72% to 82%), respectively. There w ere 10 deaths in patients allocated to BEP and 2 7 in patients allocated to CEB (log-rank x* = 8.77; P = .0 0 3 ), which led to 3-year survival rates of 97% (95% Cl, 95% to 99%) and 90% (95% Cl, 86% to 94% ), respectively.Conclusion: With these drug doses and schedules, combination chemotherapy based on carboplatin was inferior to that based on cisplatin. This BEP regimen that contains moderate doses of etoposide and bleomycin is effective in the treatment of patients with good-prognosis metastatic nonseminoma.

No abstract